At-home diagnostics startup Inito has raised $29 million in a Series B round led by Bertelsmann India Investments, with Fireside Ventures doubling down on its earlier bets. With this, the company’s total equity funding rises to $45 million, marking a strong vote of confidence in India’s emerging deep health-tech segment.

Inito first entered the market in 2021 with a breakthrough fertility device that measures four hormone markers and interprets results using its own AI-driven models. Over time, it has processed more than 30 million data points from users across the world — giving the team a uniquely rich understanding of real-world hormone patterns.

Now, co-founders Aayush Rai and Varun AV are steering the company into a much broader vision: building a platform for hormone and health diagnostics leveraging computational protein design and AI-enabled antibody engineering. Instead of relying on animal-derived antibodies and manual screening, the company is working on synthetic antibodies that are more stable, consistent and scalable — a shift that could redefine how at-home tests are built globally.

Backed by the new funding, Inito is developing diagnostics for testosterone, thyroid, vitamins and several other biomarkers, aiming to bring clinical-grade testing to the comfort of homes. With teams across Bengaluru, Dubai and London, and more than 20 patents powering its technology, the company is positioning itself as a global leader in consumer health testing.

-By Muskan Dengra